NBE-Therapeutics AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Subsidiary
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)NBE-002 in Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced Solid TumorTriple Negative Breast CancerAdvanced Cancer
- Interventions
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- NBE-Therapeutics AG
- Target Recruit Count
- 12
- Registration Number
- NCT04441099
- Locations
- 🇺🇸
Sarah Cannon Research Institute - TN Oncology, Nashville, Tennessee, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
News
No news found